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Abstract
Background: Understanding the gap between evidence-based recommendations and real-world management is
important to inform priority setting and health service planning.
Methods: The 7,776 residents in the Italian Lombardy Region who were newly hospitalized for transient ischemic
attack (TIA) during 2008–2009 entered into the cohort and were followed until 2012. Exposure to medical care
including selected drugs, diagnostic procedures and laboratory tests was recorded. A composite outcome was
employed taking into account all-cause death and hospitalization for stroke and acute myocardial infarction. A
multivariable proportional hazards model was fitted to estimate hazard ratio, and 95% confidence intervals (CI), for
the exposure-outcome association.
Results: During the first year after discharge, 8.6, 49.7 and 48.5% of patients did not use any drugs, diagnostic
procedures and laboratory tests respectively. Patients exposed to medical care had 59% reduced risk (95% CI, 50 to
66%) with respect to those who did not use any of these services.
Conclusions: Although the Italian National Health System supplies universal coverage for healthcare, several TIA
patients receive suboptimal care. Systematic improvements are necessary in order to improve patient outcomes.
Keywords: Transient ischemic attack, Healthcare utilization database, Population-based cohort study, Mortality,
Stroke, Acute myocardial infarction
Background
Observational studies have shown that transient ische-
mic attack (TIA) not only predisposes to a very high
early stroke risk [1, 2], but is also associated with long-
term increased risk of stroke, myocardial infarction and
vascular death [3–5].
Although evidence-based guidelines for acute treat-
ment and secondary prevention for TIA have been
developed along with improved diagnostic procedures
and treatments [6–10], management of TIA in clinical
practice is variable and often suboptimal [11–14].
Understanding the gap between evidence-based recom-
mendations and real-world management is therefore
important to inform priority setting and health service
planning.
We performed a population-based study, investigating
the cohort of patients discharged from hospital where
they were admitted for their first episode of acute TIA.
The purposes of the present study were to evaluate the
patterns of practice in the management of these patients,
to measure the rate of selected outcomes and to assess
the impact of the observed patterns on the risk of
selected outcomes.
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Methods
Setting
The data used for this study were retrieved from the
healthcare utilization databases of Lombardy, a region of
Italy which accounts for almost ten million individuals
(about 16% of the total population). Italian citizens are
beneficiaries of the National Health Service (NHS),
which provides universal free-of-charge coverage for
many healthcare services. Since 1997, the NHS manage-
ment in Lombardy utilizes an automated system of data-
bases that collects a variety of information, including
hospital admissions from public or private hospitals, out-
patient dispensations of drugs, visits in highly specialized
ambulatories and services in diagnostic rooms.
For each patient we linked the above databases using a
single identification code. In order to preserve privacy,
each identification code was automatically converted
into an anonymous code. The inverse process was pre-
vented by deletion of the conversion table [15]. Details
of healthcare utilization databases of the Lombardy Re-
gion and their use in the field of cardiovascular (CV)
diseases have been reported elsewhere [16–18]. Accord-
ing to the rules from the Italian Medicines Agency
(available at: http://www.agenziafarmaco.gov.it/sites/de-
fault/files/det_20marzo2008.pdf ), retrospective studies
using administrative databases do not require Ethics
Committee protocol approval.
Study cohort
All beneficiaries of the NHS who were hospitalized at
least once with a diagnosis of TIA (ICD-9th codes,
433.10, 433.30, 434.00, 434.10, 434.90, 435.x) during the
period 2008–2009 were identified, and the date of first
hospital discharge recording this diagnosis was defined
as the index date. Patients were excluded whether: (1)
they already experienced any cerebrovascular
hospitalization in the eight years preceding the index
date; (2) they were admitted for a planned hospital
access (i.e., only patients who had access to the hospital
from emergency wards were included); (3) they died
during the index admission. The remaining patients con-
stituted the study cohort.
Each cohort member was followed from the index
date until censoring, i.e., the earliest among the dates
of outcome onset (see below), emigration, or
December 31st, 2012.
The outcome was experienced by cohort members
who during follow-up died for any cause or were hospi-
talized for stroke (ICD-9th codes, 430–434 except
433.10, 433.30, 434.00, 434.10, 434.90) or acute myocar-
dial infarction (AMI) (ICD-9th code 410). A patient who
experienced at least one of these events was considered
as having the outcome. The earliest date of hospital
admission for these events was considered as the time of
outcome.
Reference cohort
A reference cohort suitable to be used as comparator for
the study cohort was generated. Reference cohort mem-
bers were NHS beneficiaries 1:1 matched on gender and
age at cohort entry with TIA cohort members, who did
not yet experience hospitalization for TIA at index date
and were at risk for the outcome at the time when the
matched TIA patient was discharged. Each member of
the reference cohort was followed for identifying those
who experienced the considered outcomes exactly as de-
scribed for the study cohort.
Baseline characteristics and healthcare exposures
Gender, age, nationality (Italian born or migrant), and
the Charlson comorbidity index score [19] calculated by
using the diagnostic information available from inpatient
charts in the five-year period prior the index date, were
recorded at baseline for each study and reference cohort
member. During the one-year periods before and after
the date of the index hospital admission, as well as dur-
ing the entire period of follow-up, we recorded the fol-
lowing information: (i) use of selected drugs (blood
pressure- and lipid-lowering agents, antiplatelet, oral an-
ticoagulants and antiarrhythmic drugs and antidiabetics);
(ii) exposure to diagnostic procedures (i.e., carotid,
transcranial and cardiac doppler ultrasonography, neuro-
imaging – computed tomography or magnetic resonance
imaging – or cerebral angiography, and electrocardiog-
raphy); and (iii) laboratory tests (i.e., total cholesterol
and glycated haemoglobin).
Data analysis
McNemar chi-square test for matching pairs was used
to compare healthcare exposures experienced by (i)
study and reference cohort during the one-year period
before the index date, (ii) study cohort one year before
and one year after the index date.
Chi-square test was used to compare the proportion of
study cohort members who did not use healthcare ser-
vices according to gender, age (patients younger or older
70 years), and Charlson comorbidity index score (none
or at least one sign of comorbidity).
The cumulative probability of experiencing a specific
outcome (i.e., death or hospital admission for stroke or
AMI) during follow-up was estimated by the competing
risks method [20]. With this approach a subject was as-
sumed to experience the outcome only once, and the
overall incidence at a given time was split into the sum
of the cause-specific cumulative incidences.
Finally, the Cox proportional hazard regression was
used to estimate the hazard ratio (HR) and 95%
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confidence interval (CI), for the association between
healthcare exposure and time of the outcome onset (i.e.,
the earliest date between those of death or hospital
admission for stroke or AMI). Because exposure to
healthcare varies over time, assessment of its value re-
quires proper accounting for the cumulative and varying
nature of the measure. This was done by including
healthcare exposure categories as time-dependent vari-
ables in the model [21]. Adjustment was made for the
baseline characteristics by including the corresponding
covariates into the model. For each time-fixed covariate
included in a Cox proportional hazards model, the
proportionality assumption was assessed graphically by
survival curves (Kaplan-Meier method).
To verify the robustness of our findings, the aforemen-
tioned analysis was limited to those patients who during
the index hospital admission were underwent to com-
puted tomography and/or magnetic resonance imaging
and/or cerebral angiography.
For all hypotheses tested, two-tailed p-values less than
0.05 were considered as significant.
Results
Among the 19,767 patients hospitalized with a diagnosis
of TIA during the period 2008–2009, 11,991 were
excluded; 5,822 (48.5%) because they had previous cere-
brovascular hospitalization; 6,038 (50.4%) because they
were admitted for a planned hospital access; and 131
(1.1%) because they died during the index admission.
The remaining 7,776 patients formed the study cohort.
At baseline, their mean age was 73.3 years (SD,
13.0 years, range 18–101 years), 52.9% of them were
women, 96.6% was Italian native and 89.3% of them did
not have signs of comorbidities. During the index
hospital admission 6,063 patients (78.0%) were under-
went to at least a neuroimaging procedure, 4,808
(61.8%) to computed tomography only, 395 (5.1%) to
magnetic resonance only, 828 (10.6%) to both computed
tomography and magnetic resonance and 36 (0.5%) to
cerebral angiography.
Table 1 shows that one year before the index
hospitalization, study cohort members had significantly
higher use of healthcare services than the corresponding
reference cohort members, except for exposure to lipid-
lowering agents. As a consequence, there was statistical
evidence that prevalence of patients who did not use
drugs, diagnostic procedures and/or laboratory tests was
significantly higher among reference than TIA study co-
hort members. From one year before to one year after
the index hospital admission for TIA, study cohort
Table 1 Comparison of healthcare exposure of reference cohort (A) and transient ischemic attack (TIA) study cohort before (B) and
after (C) index hospitalization
Reference cohort TIA study cohort p-value
One year before index
hospitalization (A)
One year before index
hospitalization (B)
One year after index
discharge (C)
(A vs. B) (B vs. C)
Drugs
Blood pressure-lowering agents 4,544 (58.4%) 5,255 (67.6%) 5,819 (74.8%) <0.0001 <0.0001
Lipid-lowering agents 1,358 (17.5%) 1,446 (18.6%) 2,651 (34.1%) 0.0612 <0.0001
Antiplatelet drugs 2,162 (27.8%) 2,754 (35.4%) 5,926 (76.2%) <0.0001 <0.0001
Oral anticoagulants 421 (5.4%) 499 (6.4%) 997 (12.8%) 0.0077 <0.0001
Antiarrhythmics 345 (4.4%) 416 (5.3%) 535 (6.9%) 0.0082 <0.0001
Antidiabetics 867 (11.1%) 1,233 (15.9%) 1,300 (16.7%) 0.0192 0.0002
None of the previous 2,720 (35.0%) 1,958 (25.2%) 667 (8.6%) <0.0001 <0.0001
Diagnostic procedures
Cardiac doppler ultrasonography 690 (8.9%) 845 (10.9%) 1,075 (13.8%) <0.0001 <0.0001
Carotid doppler ultrasonography 633 (8.1%) 759 (9.8%) 1,172 (15.1%) 0.0004 <0.0001
Neuroimaging or cerebral angiography 156 (2.0%) 277 (3.6%) 769 (9.9%) <0.0001 <0.0001
Electrocardiogram 1,739 (22.4%) 2,396 (30.8%) 2,525 (32.5%) <0.0001 0.0119
None of the previous 5,465 (70.3%) 4,744 (61.0%) 3,863 (49.7%) <0.0001 <0.0001
Laboratory tests
Total cholesterol 3,622 (46.6%) 3,827 (49.2%) 3,698 (47.6%) 0.0007 0.0149
Glycosylated haemoglobin, Type A1C 1,070 (13.8%) 1,339 (17.2%) 1,434 (18.4%) <0.0001 0.0024
None of the previous 3,958 (50.9%) 3,720 (47.8%) 3,775 (48.5%) <0.0001 0.1947
None of the previous drugs, diagnostic procedures,
nor laboratory tests
1,652 (21.2%) 1,104 (14.2%) 388 (5.0%) <0.0001 <0.0001
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members increased the exposure to healthcare services.
There was evidence that the number of patients who did
not experience use of drugs and/or diagnostic proce-
dures diminished after hospital admission for TIA, even
if the proportion of individuals who did not undergo
laboratory tests did not change during the considered
time-frame. During the first year after discharge, of the
7,776 patients of the study cohort, 667 (8.6%) did not
use any medication, 3,863 (49.7%) any diagnostic pro-
cedure, and 3,775 (48.5%) any laboratory test, while 388
of them (5.0%) did not show any evidence of exposure
to none of the considered healthcare services. The latter
were mainly represented by women and elderly, being
the prevalence of healthcare no users 4.2 and 5.7%
among men and women respectively (p = 0.0029) and 4.3
and 5.4% among patients younger and older than
70 years respectively (p = 0.0355). There was no evidence
that prevalence of healthcare no users differed among
patients with or without signs of comorbidity.
During the observation period, the study and reference
cohort members accumulated 25,306 and 25,725 person-
years of follow-up (in average 3.3 and 3.5 years per
patient respectively) and generated 2,353 and 1,557 out-
comes. Cumulative incidences are shown in Fig. 1.
Among the study cohort members, cumulative mortality
and hospital readmission for stroke or AMI were re-
spectively 7.4, 3.3 and 0.7% after 1 year, and 24.5, 7.6
and 2.6% after 5 years from the index discharge. Among
the reference cohort members, the corresponding figures
were 4.3, 0.6 and 0.6% after 1 year, and 18.8, 2.4 and
2.1% after 5 years from the index discharge. The cumu-
lative composite incidence rate was 2.1-fold and 1.5-fold
higher among the study cohort than the reference cohort
within 1 year and 5 years after the index discharge,
respectively.
Figure 2 shows that TIA cohort members who experi-
enced exposure to selected drugs (lipid-lowering agents,
antiplatelet and oral anticoagulants) and diagnostic pro-
cedures (i.e., carotid and cardiac doppler ultrasonog-
raphy) during follow-up had significant lower risk of the
composite outcome than those who did not use these
services. Conversely, patients who took antidiabetics and
antiarrhythmics, those who underwent electrocardiog-
raphy, and those tested for glycosylated haemoglobin,
type A1C levels (HbA1C), were at higher risk.
The joint action of exposure to whichever drug, diag-
nostic procedure and laboratory test on the risk of the
composite outcome is shown in Fig. 3. Patients who dur-
ing follow-up used at least a drug, a diagnostic proced-
ure and a laboratory test had a 59% reduced risk (95%
CI, 50 to 66%) with respect to those who did not use
any of these services. Drug therapies exerted higher pro-
tective action than other services since patients who
took drugs, but neither used diagnostic procedure nor
laboratory tests, had a significant reduced risk of 38%
(95% CI, 28 to 47%).
The risk reduction was confirmed by including the
6,063 patients who during the index hospital admission
were underwent to neuroimaging, having exposed to
medical care of this subgroup a 54% reduced risk (95%
Fig. 1 Cumulative mortality and hospital readmission for stroke and acute myocardial infarction (AMI) among study and reference cohort members
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CI, 42 to 64%) with respect to those who did not use
any medical services.
Discussion
Our study shows that: (i) management of TIA in daily
clinical practice of the Italian Lombardy Region is
suboptimal since in the first year after discharge little
less than one in ten patients (8.6%) did not use blood
pressure- and lipid-lowering agents, antidiabetics, anti-
platelet and oral anticoagulants, nearly half of them
(49.7%) have not been underwent to diagnostic procedures
such as carotid and cardiac doppler ultrasonography,
while one in twenty of them (5.0%) did not show any evi-
dence of exposure to drugs, diagnostic procedures nor
laboratory tests; (ii) patients with TIA diagnosed in
hospital represent a high-risk group since 11.4 and 34.7%
of them died or was hospitalized for stroke or AMI within
1 year and 5 years from index discharge respectively; (iii)
the onset of a TIA represents a special opportunity for
preventive intervention, since patients who used drug
therapies and diagnostic procedures commonly recom-
mended by guidelines showed a 59% risk reduction of
Fig. 2 Hazard ratio (and 95% confidence interval) for the association between healthcare exposure and time of the composite outcome onset
Fig. 3 Joint action of exposure to whichever drug, diagnostic procedure and laboratory test on the risk of the composite outcome
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death or cardiovascular hospitalization with respect to
those who did not use any medical device.
A growing body of literature confirms the high rates
of death and re-hospitalization during the first year after
TIA. Patients recruited into clinical trials after a TIA
have an annual risk of important vascular events (death
from all vascular causes, non-fatal stroke, or non-fatal
myocardial infarction) between 4 and 11% [22–24]. Simi-
lar figures have been reported from population-based
observational studies being the corresponding rate
around 9% per year [25], while the 10-year risk of stroke,
myocardial infarction, or vascular death was reported to
be 43% [5]. Our study supports the available data show-
ing that patients discharged with a diagnosis of TIA had
from 1.5-fold to 2.1-fold higher risk of unfavourable out-
comes with respect to individuals of the same age and
gender with no signs of cerebrovascular event.
Because medicines, diagnostic and screening investiga-
tions play an important role in secondary prevention for
TIA patients [26–29], changes to the usual medicine
regimen and diagnostic procedures can be expected for
them [30]. Consistently, our study showed that users of
blood pressure- and lipid-lowering agents, antiplatelet
therapy, cardiac and carotid doppler ultrasonography
and screening for diabetes and hyperlipidaemia in-
creased after TIA occurrence. However, similarly to
other reports [31–33], our findings show that several
patients did not receive even one of these drugs and
diagnostic procedures within one year after discharge.
Other findings are noteworthy and also warrant
discussion. First, adverse outcomes were reduced of
more than a 25% among patients who were treated with
lipid-lowering, antiplatelet and anticoagulant agents. Al-
though this is an expected finding according to current
evidence-based recommendations on the prevention of
future stroke among survivors of ischemic stroke or TIA
[34], we suspect that the observed protective effect
might be in part explained by the fact that drug expo-
sures likely reflect general medical attention. This would
explain because a similar protective effect was conferred
by so different therapeutic actions. Second, patients who
during follow-up used antidiabetic agents, as well as
those who underwent a screening with glycosylated
haemoglobin (HbA1C), were at higher risk for the
considered outcomes likely because diabetes is known to
be associated with unfavourable consequences after a
cerebrovascular event occurs [35]. Analogously, patients
who during follow-up used antiarrhythmic agents, and
those who underwent electrocardiography, had worse
prognosis likely because these exposures are proxies of
high cardiac risk. Third, we observed that during the
one-year period before the TIA occurrence, patients at
their first episode of TIA (cases) had higher use of drugs
for treating hypertension, cardiac arrhythmias and type
2 diabetes mellitus than patients who did not show evi-
dence of cerebrovascular outcomes (controls). This find-
ing supports the important role of hypertension,
arrhythmias and diabetes as risk factors for TIA [36–38],
confirming the potential benefits of primary prevention
through the control of these conditions.
The present study has several elements of strength.
First, the investigation was based on a very large unse-
lected population, which was made possible because in
Italy a cost-free healthcare system involves virtually all
citizens. Second, the drug prescription database provided
highly accurate data, because pharmacists are required
to report prescriptions in detail in order to obtain reim-
bursement, and incorrect reports about the dispensed
drugs have legal consequences [39]. Third, patients were
included if there was no previous evidence of cerebro-
vascular disease over several years, which makes our
results relevant in the setting of primary prevention of
stroke. Finally, patients were identified from the point of
the first episode of hospitalization for TIA and the
complete sequence of following healthcare services sup-
plied by the NHS was known.
Our study has also some limitations. One, because of
privacy regulations, hospital records were not available
for scrutiny, which means that diagnosis of TIA could
not be checked. Owing the lack of evidence from up-to-
date studies performed in the healthcare system of the
Region we study, misclassification cannot be completely
excluded in our setting. For example, if benign condi-
tions (e.g., migraine, syncope and seizure) were mistaken
for TIA [40], a portion of patients at low risk had been
included in our cohort. Although our main result was
confirmed by including patients underwent to neuroim-
aging at the index hospitalization, the lack of clinical
information useful for risk stratification and prognostica-
tion, is a main cause of systematic uncertainty of our
study.
Two, not all patients who experience a TIA are
hospitalized [41], thus implying that our study selectively
included more severe patients, and/or those at whom
more clinical attention was reserved. Three, drug treat-
ment was derived from drug prescriptions, which re-
quires, however, the assumption that drug prescription
corresponds to drug consumption [42]. There is, how-
ever, no guarantee that this is always the case, and
indeed it is likely that in a number of patients the
prescribed drugs are not consumed. This implies, how-
ever, that in the real-world, the actual use of medicines
may be even still less than the measured prevalence of
drug users.
Finally, the more relevant question in interpreting our
findings is whether the observed results are due to our
inability to fully account for lower adherence with guide-
lines to those patients at higher risk of adverse
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outcomes. That is, the reduction in adverse outcome as-
sociated with a better adherence to guidelines and a
higher use of healthcare services might rather have been
generated by a worse clinical profile, e.g., the severity of
ischemic lesion and comorbidities. Yet, TIA clinical
presentation (i.e., anterior circulation/posterior circula-
tion TIA) could affect the adherence to medicaments,
since, as well known, posterior circulation TIA are often
misdiagnosed, representing a challenge in vascular neur-
ology [43, 44]. However, because it is well known that
patients with worse clinical profile more likely adhere to
medical care [45], the observed risk reduction might be
larger than that quantified by our study. Thus, our
results are likely to reflect the favourable effect offered
by healthcare services based on guidelines on cardiovas-
cular protection.
Conclusion
In summary, our findings suggest the need for intensive
medical attention after TIA occurrence in an effort to
prevent disabling stroke, other cardiovascular accidents
and death. Patient outcomes may be improved by efforts
aimed at increasing both patient and provider adherence
to evidence-based guidelines.
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